Sinocelltech Group Ltd (688520) - Total Assets
Based on the latest financial reports, Sinocelltech Group Ltd (688520) holds total assets worth CN¥3.76 Billion CNY (≈ $550.42 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688520 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Sinocelltech Group Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's total assets have evolved over time, based on quarterly financial data. Check Sinocelltech Group Ltd (688520) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Sinocelltech Group Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinocelltech Group Ltd's total assets of CN¥3.76 Billion consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.6% |
| Accounts Receivable | CN¥745.59 Million | 22.7% |
| Inventory | CN¥259.49 Million | 7.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥204.00 Million | 6.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sinocelltech Group Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinocelltech Group Ltd's current assets represent 44.5% of total assets in 2024, an increase from 21.7% in 2016.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2024, down from 10.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 4.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 22.7% of total assets.
Sinocelltech Group Ltd Competitors by Total Assets
Key competitors of Sinocelltech Group Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Sinocelltech Group Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.61 | 0.71 | 2.32 |
| Quick Ratio | 0.50 | 0.59 | 2.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-1.17 Billion | CN¥-576.01 Million | CN¥576.18 Million |
Sinocelltech Group Ltd - Advanced Valuation Insights
This section examines the relationship between Sinocelltech Group Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 215.76 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | 20.8% |
| Total Assets | CN¥3.28 Billion |
| Market Capitalization | $2.23 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sinocelltech Group Ltd's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sinocelltech Group Ltd's assets grew by 20.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual total assets of Sinocelltech Group Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.28 Billion ≈ $480.55 Million |
+20.80% |
| 2023-12-31 | CN¥2.72 Billion ≈ $397.81 Million |
-0.63% |
| 2022-12-31 | CN¥2.74 Billion ≈ $400.34 Million |
+99.24% |
| 2021-12-31 | CN¥1.37 Billion ≈ $200.94 Million |
-17.45% |
| 2020-12-31 | CN¥1.66 Billion ≈ $243.42 Million |
+105.83% |
| 2019-12-31 | CN¥808.19 Million ≈ $118.26 Million |
+49.73% |
| 2018-12-31 | CN¥539.76 Million ≈ $78.98 Million |
+10.85% |
| 2017-12-31 | CN¥486.94 Million ≈ $71.25 Million |
+15.48% |
| 2016-12-31 | CN¥421.68 Million ≈ $61.70 Million |
-- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more